These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 17208578

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction.
    Hisanaga T, Shinjo T, Morita T, Nakajima N, Ikenaga M, Tanimizu M, Kizawa Y, Maeno T, Shima Y, Hyodo I.
    Jpn J Clin Oncol; 2010 Aug; 40(8):739-45. PubMed ID: 20410056
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Octreotide in the management of bowel obstruction in terminal ovarian cancer.
    Mangili G, Franchi M, Mariani A, Zanaboni F, Rabaiotti E, Frigerio L, Bolis PF, Ferrari A.
    Gynecol Oncol; 1996 Jun; 61(3):345-8. PubMed ID: 8641613
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics.
    Weber C, Zulian GB.
    Am J Hosp Palliat Care; 2009 Jun; 26(2):84-8. PubMed ID: 19088264
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.
    Peng X, Wang P, Li S, Zhang G, Hu S.
    World J Surg Oncol; 2015 Feb 15; 13():50. PubMed ID: 25889313
    [Abstract] [Full Text] [Related]

  • 15. SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction.
    Laval G, Rousselot H, Toussaint-Martel S, Mayer F, Terrebonne E, François E, Brixi H, Nguyen T, Bourdeix I, Bisot-Locard S, Zelek L, SALTO Study Group.
    Bull Cancer; 2012 Feb 01; 99(2):E1-9. PubMed ID: 22265994
    [Abstract] [Full Text] [Related]

  • 16. [A case of obstruction due to right-sided colon cancer in which good quality of life was achieved after colonic stenting].
    Nakao S, Hori T, Miura K, Tendo M, Nakata B, Ishikawa T, Hirakawa K.
    Gan To Kagaku Ryoho; 2013 Nov 01; 40(12):2059-61. PubMed ID: 24394012
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Medical Therapy of Malignant Bowel Obstruction With Octreotide, Dexamethasone, and Metoclopramide.
    Berger J, Lester P, Rodrigues L.
    Am J Hosp Palliat Care; 2016 May 01; 33(4):407-10. PubMed ID: 25646530
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer.
    Kubota H, Taguchi K, Kobayashi D, Naruyama H, Hirose M, Fukuta K, Kubota Y, Yasui T, Yamada Y, Kohri K.
    Asian Pac J Cancer Prev; 2013 May 01; 14(12):7107-10. PubMed ID: 24460259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.